Collecting bone marrow samples from patients with Myelodysplastic Syndrome

Collection of Samples of Bone Marrow Aspiration From Patients With Myelodysplastic Syndrome

This study is collecting bone marrow and blood samples from patients with Myelodysplastic Syndrome to see if boosting mitochondrial function can help improve their condition.

Quick facts

• Study type: Observational
• Enrollment: 100 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Minovia Therapeutics Ltd. (Industry-sponsored)
• Locations: 1 site (Jerusalem)
• Trial ID: NCT06144515 on ClinicalTrials.gov

What this trial studies

This study aims to collect bone marrow aspirates and peripheral blood samples from patients diagnosed with Myelodysplastic Syndrome (MDS) to investigate mitochondrial function and the effects of mitochondrial augmentation therapy. Mitochondrial dysfunction is linked to MDS, and the research will explore the role of mitochondrial DNA mutations in disease progression. The study will involve in vitro and in vivo analyses of the collected samples, focusing on the potential therapeutic benefits of augmenting hematopoietic stem and progenitor cells with mitochondria from donor sources.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older who have been diagnosed with or are suspected to have Myelodysplastic Syndrome.

Not a fit: Patients with a history of prior allogeneic hematopoietic stem cell transplantation, cell therapy, or gene therapy may not benefit from this study.

Why it matters

Potential benefit: If successful, this research could lead to new therapeutic strategies targeting mitochondrial dysfunction in patients with Myelodysplastic Syndrome.

How similar studies have performed: While mitochondrial augmentation therapy is a novel approach, previous studies have indicated potential benefits of targeting mitochondrial dysfunction in hematopoietic disorders, suggesting a promising avenue for exploration.

Eligibility criteria

Inclusion Criteria:

1. Male or female patients of 18 years old and up.
2. Suspected or previously diagnosed with Myelodysplastic Syndrome.
3. Patient able to understand and provide voluntary written informed consent.

Exclusion Criteria:

1. History of prior allogeneic hematopoietic stem cell transplantation, cell therapy, gene therapy.

Where this trial is running

Jerusalem

• Shaare Zedek Medical Center — Jerusalem, Israel (Recruiting)

Study contacts

• Study coordinator: Lea Bensoussan, MSc

Conditions Myelodysplastic Syndromes; Mitochondrial; Research